Poseida Therapeutics to Present at Two Upcoming Investor Conferences
Poseida Therapeutics (Nasdaq: PSTX), a clinical-stage company focused on allogeneic cell therapy and genetic medicines, has announced its participation in two major healthcare investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Poseida Therapeutics (Nasdaq: PSTX), a clinical-stage company focused on allogeneic cell therapy and genetic medicines, has announced its participation in two major healthcare investor conferences. The company will present at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024, at 10:20am ET, and the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 12:00pm ET.
Webcasts of both presentations will be accessible through Poseida's website and will remain available for approximately 90 days after the events.
Details
News Market Reaction – PSTX
The recorded move for PSTX in the trading session of this news was -0.54%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Stifel 2024 Healthcare Conference
Date: Monday, November 18, 2024
Time: 10:20am ET
Piper Sandler 36th Annual Healthcare Conference
Date: Wednesday, December 4, 2024
Time: 12:00pm ET
Webcasts will be available on the Investors & Media Section of Poseida's website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company's pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumors, as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral transposon-based DNA delivery system, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. Learn more at www.poseida.com and connect with Poseida on X and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-two-upcoming-investor-conferences-302301700.html
SOURCE Poseida Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.